FDA Submission Update for Dalfampridine by Accord Healthcare
Accord Healthcare has submitted an Abbreviated New Drug Application (ANDA) for Dalfampridine, currently under standard review.
Asset
Dalfampridine
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Portfolio teams should assess the competitive landscape for Dalfampridine and consider strategies to mitigate potential market share loss.
Why it matters
The submission of an ANDA for Dalfampridine by Accord Healthcare signals the potential entry of a generic competitor into the market. This could lead to significant pricing pressures and market share erosion for current brand holders, necessitating strategic responses.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any subsequent approval announcements for the ANDA.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.